Comparative Pharmacology
Head-to-head clinical analysis: CONJUGATED ESTROGENS versus ESTRACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONJUGATED ESTROGENS versus ESTRACE.
CONJUGATED ESTROGENS vs ESTRACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Conjugated estrogens bind to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting estrogenic effects on target tissues, including the endometrium, breast, and bone. They increase hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin, and other proteins, and have effects on lipid metabolism, coagulation factors, and vasodilation via nitric oxide.
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
0.625 mg orally once daily for menopausal symptoms; 1.25 mg orally three times daily for 2-3 weeks for abnormal uterine bleeding; 25 mg intravenously or intramuscularly every 6-12 hours for postpartum hemorrhage.
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
None Documented
None Documented
10–24 hours (terminal); clinical context: requires daily dosing for stable hormone levels.
Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement.
Renal: 40–50% as glucuronide conjugates; biliary/fecal: ~20% as free and conjugated forms.
Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%).
Category D/X
Category C
Estrogen
Estrogen